
BioCryst Pharmaceuticals has announced plans to discontinue its internal discovery programmes and close its Discovery Center of Excellence facility in Birmingham, Alabama by the end of 2026. The company says the moves are part of an ongoing strategic evolution to strengthen its rare disease pipeline. It has determined that prioritising… Read More

In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More

Laboratory automation has been one of the most significant developments in laboratory sciences in recent years, enhancing process quality, eliminating human error and variability, and ultimately making operations more cost-effective and efficient. However, as automation tools become more advanced and complex, this can create connectivity issues and disrupt existing workflows, potentially preventing seamless connection with… Read More

Anthropic has launched Claude Science, an app that it says integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources. At the launch event, the company also announced that it will be using the product to pursue some of its… Read More

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More

As DDW launches its new event series Drug Discovery Innovators & Investors, Lu Rahman looks at the challenges and opportunities that exist for both drug developers and investors looking to bring a new drug to market. It’s no news that the discovery and development of a new drug is not only costly and lengthy - over $1… Read More

In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More

In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More

By Angie Reynolds, Chief Operating Officer at University of Birmingham Enterprise and Board Director at the UK Science Park Association (UKSPA). Birmingham Research Park is celebrating its 40th anniversary this year. Any milestone creates an opportunity to take stock about where you’ve come from and where you’re going – which seems timely given ongoing debates about what a difference location makes in an… Read More

By Sandy Tammisetty, VP of the Veeva Services Practice Group at Conexus Solutions. Artificial intelligence (AI) is no longer a future concept in clinical trials. It is already influencing how clinical data is reviewed, monitored, and analysed, particularly as trials become more complex and data volumes continue to grow. From anomaly detection to advanced… Read More

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

By Carolina Lucchesi, Principal Scientist and Head of Microphysiological Systems, ATCC. Across the world, regulators are sending a consistent signal: the era of animal-only preclinical testing is drawing to a close. In the United States, the Food and Drug Administration (FDA) has committed to phasing out animal testing requirements1. The European Union and United Kingdom are moving in the same direction, with regulatory bodies… Read More

Drug Discovery World (DDW) is launching new series of events aimed at connecting innovation with investment in early-stage drug discovery. The Drug Discovery Innovators and Investors three-part series will comprise a digital forum (30 September 2026), and two in-person events (London, UK, 4 November 2026, and Basel, Switzerland, March 2027). Read More

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across… Read More